<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626938</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 04-145.11</org_study_id>
    <nct_id>NCT00626938</nct_id>
  </id_info>
  <brief_title>Role of Proteomics in Diagnosing Sarcoidosis</brief_title>
  <official_title>Proteomics as a Tool for Biomarker Detection in Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a multi-systemic disorder, meaning that it can involve any organ in the body
      and that its clinical presentation is highly variable. In 90% of all sarcoidosis cases the
      lungs are affected. It is difficult to give a concise definition of sarcoidosis due to the
      fact that its exact cause is still unknown. Consequently, diagnosing the disease is also
      rather difficult. Up till now, sarcoidosis is generally diagnosed by using general clinical
      methods to evaluate the status of the lung including a chest X-ray, lung biopsy and
      bronchoalveolar lavage (BAL). However, some of these methods are considered to be rather
      invasive and, even more important, non-conclusive. Therefore, the current study has been
      designed to evaluate the use of a new technique, called SELDI-TOF mass spectrophotometry, for
      the diagnosis of sarcoidosis. This technique enables the analysis of all enzymes present in
      the blood of sarcoidosis patients which may hopefully lead to creating a disease-specific
      protein-profile that may facilitate the recognition of sarcoidosis. Moreover, these results
      will be compared with other currently used laboratory parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>protein profile in blood</measure>
    <time_frame>within 1 month after obtaining sample</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CYP and TNF polymorphisms</measure>
    <time_frame>within 6 months after obtaining sample</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>sarcoidosis</arm_group_label>
    <description>sarcoidosis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>healthy volunteers and other interstitial lung disease (ILD) patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be collected from all participants, but all samples will be stored anonymously.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients visiting the out-patient clinic of the university hospital Maastricht.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of pulmonary sarcoidosis stage I-IV

        Exclusion Criteria:

          -  Non-smoking

          -  No treatment for extra-pulmonary symptoms of sarcoidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjolein Drent, Prof,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Maastricht, Departement of Respiratory Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otto Bekers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Maastricht, Departement of Clinical Chemistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Voorter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Maastricht, Departement of Tissue Typing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marja P van Dieijen-Visser, Prof,MSc,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Maastricht, Departement of Clinical Chemistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ildcare.eu</url>
    <description>official site of ildcare foundation, ild= interstitial lung disease</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>marjolein drent</investigator_full_name>
    <investigator_title>Prof. Marjolein Drent</investigator_title>
  </responsible_party>
  <keyword>sarcoidosis</keyword>
  <keyword>protein profile</keyword>
  <keyword>CYP-450</keyword>
  <keyword>TNF-alpha polymorphisms</keyword>
  <keyword>HLA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

